Notably, emerging evidence indicates that TCL1A overexpression serves as a negative prognostic indicator not only in B-cell malignancies (27) but also in various solid tumors (30–32), where it promotes tumor progression through modulating immune microenvironment and enhancing cell survival pathways. The gene discussed is TCL1A; the disease is neoplasm.